PERSPECTIVE THERAPEUTICS, INC.
Moat Score — Perspective Therapeutics, Inc.
Total Moat Score
10 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Perspective holds Fast Track designations on two lead programs and a validating $28 million upfront partnership with Lantheus, but none of its candidates are yet approved, so its intellectual property has not yet converted into a commercialized, protected franchise. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 3 / 5 | A 10-year Thorium-228 feedstock supply contract and owned CGMP manufacturing suites address the scarce Lead-212 isotope supply bottleneck facing the alpha-therapy field, giving Perspective a real production-cost and availability edge over developers reliant on third-party isotope sourcing. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | With no approved products and no commercial revenue, Perspective has no demonstrated pricing power yet; any future pricing would depend on clinical outcomes and payer negotiations typical of specialty oncology therapeutics. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Radiopharmaceutical drug development carries no network effect between patients or providers. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | As a pre-commercial company, Perspective has not yet established prescriber or patient switching costs; any future stickiness would depend on clinical differentiation once products reach market. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The alpha-emitter radiopharmaceutical niche has few companies with integrated isotope production capability, which somewhat limits new entrants, but well-capitalized giants like Novartis and Bristol Myers Squibb are already investing heavily in the broader radioligand therapy category. |